Innovative beverage creation through symbiotic microbial communities inspired by traditional fermented beverages: current status, challenges and future directions

Review

作者: Li, Menghui ; Cai, Rui ; Wang, Zhouli ; Wang, Kai ; Wang, Xingnan ; Wang, Leran ; Liu, Xiaoshuang ; Li, Shiqi ; Yuan, Yahong ; Yue, Tianli

Fermented beverages (FBs) are facing challenges in functional performance and flavor complexity, necessitating the development of new multi-functional options. Traditional fermented beverages (TFBs), both alcoholic and nonalcoholic, have gained increased attention for their health-promoting effects during the COVID-19 pandemic. This review summarized the primary commercially available probiotics of FBs, along with the limitations of single and mixed probiotic FBs. It also examined the recent research progress on TFBs, emphasizing the typical microbial communities (MC) of TFBs, and TFBs made from crops (grains, vegetables, fruits, etc.) worldwide and their associated functions and health benefits. Furthermore, the construction, technical bottlenecks of the synthetic MC involved in developing innovative FBs were presented, and the promising perspective of FBs was described. Drawing inspiration from the MC of TFBs, developing of stable and multifunctional FBs using synthetic MC holds great promise for beverage industry. However, synthetic MC suffers from structural instability and poorly acknowledged interaction mechanisms, resulting in disappointing results in FBs. Future researches should prioritize creating synthetic MC fermentation that closely resemble natural fermentation, tailored to meet the needs of different consumers. Creating personalized FBs with high-tech intelligence is vital in attracting potential consumers and developing novel beverages for the future.

2024-09-01·Digestive and Liver Disease

Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced HCC: A real-life comparison with best supportive care

Article

作者: Brandi, Giovanni ; Campani, Claudia ; Pelizzaro, Filippo ; Vidili, Gianpaolo ; Nardone, Gerardo ; Giannini, Edoardo G ; Sangiovanni, Angelo ; Biasini, Elisabetta ; Vitale, Alessandro ; Masotto, Alberto ; Guarino, Maria ; Santi, Valentina ; Saitta, Carlo ; Mega, Andrea ; Magalotti, Donatella ; Bucci, Laura ; Cabibbo, Giuseppe ; Lani, Lorenzo ; Di Marco, Mariella ; Trevisani, Franco ; Granito, Alessandro ; Sacco, Rodolfo ; Stefanini, Benedetta ; Sabbioni, Simone ; Rapaccini, Gian Ludovico ; Gasbarrini, Antonio ; Azzaroli, Francesco ; Ghittoni, Giorgia ; Reggidori, Nicola ; Foschi, Francesco Giuseppe ; Svegliati-Baroni, Gianluca

BACKGROUND AND AIMSThe efficacy of systemic therapy for unresectable advanced hepatocellular carcinoma (aHCC) has not been proven in patients with Child-Pugh (C-P) B cirrhosis. Nevertheless, in real-world these patients are treated both with tyrosine kinase inhibitors (TKIs) and with metronomic capecitabine (MC). This study aimed to compare sorafenib and MC outcomes versus best supportive care (BSC) in C-P B patients.METHODBetween 2008 and 2020, among 774 C-P B patients with aHCC not amenable/responsive to locoregional treatments, 410 underwent sorafenib, 62 MC, and 302 BSC. The propensity score matching method was used to correct the baseline unbalanced prognostic factors.RESULTSIn the unmatched population, median OS was 9.7 months in patients treated with sorafenib, 8.0 with MC, and 3.9 months with BSC. In sorafenib vs. BSC-matched patients (135 couples), median OS was 7.3 (4.9-9.6) vs. 3.9 (2.6-5.2) months (p<0.001). ECOG-Performance Status, tumor size, macrovascular invasion, AFP, treatment-naive, and sorafenib were independent predictors of survival. In MC vs. BSC-matched patients (40 couples), median OS was 9.0 (0.2-17.8) vs.3.0 (2.2-3.8) months (p<0.001). Median OS did not differ (p = 0.283) in sorafenib vs. MC-matched patients (55 couples).CONCLUSIONC-P B patients with aHCC undergoing BSC have poor survival. Both Sorafenib and MC treatment improve their prognosis.

2024-09-01·BMJ Supportive & Palliative Care

Medical cannabis for refractory cancer-related pain in a specialised clinical service: a cross-sectional study

Article

作者: Brill, Silviu ; Sharon, Haggai ; de Santiago, Jesus ; Hochberg, Uri ; Agbaria, Yara

Background and objectivesCancer-related pain management in advanced stages presents a significant challenge that often requires a multidisciplinary approach. Although advancements in pharmacological and interventional therapies, a considerable number of patients still suffer from refractory pain, leading to unmet clinical needs. This study shares our experience with medical cannabis (MC) as a potential therapy for this specific population of patients with cancer-related refractory pain.MethodsIn a cross-sectional study, 252 consecutive refractory cancer-related pain patients (mean age=61.71, SD=14.02, 47.6% males) filled out detailed self-report questionnaires. Of these, 126 patients (55%) were treated with MC and 105 patients (45%) were not.ResultsMost patients received pain management from their oncologist, not a pain specialist. MC was mainly started for pain relief, sleep difficulties and anorexia. About 70% of patients reported subjective improvement from MC, with almost 40% reporting a significant improvement in coping with their illness. Side effects were generally mild, with fatigue and dizziness being the most common (21.78% and 23.46%, respectively). No patient required dedicated medical care for side effects. Of non-users, 65% had tried MC before and stopped due to lack of effectiveness or side effects (39.7% and 34.6%, respectively).ConclusionRefractory cancer pain necessitates innovative approaches. This registry highlights that MC can effectively improve symptoms in non-responsive patients, with favourable safety profiles for this vulnerable population.

100 项与乾燥濃縮人血液凝固第Ⅷ因子（生物学的製剤基準）相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
血友病A	日本	The Japan Blood Products Organization	2013-03-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2011	临床2期	HER2 阴性乳腺癌一线 \| 维持	15	mC plus D	(願獵壓鏇壓艱襯淵獵淵) = 餘憲廠衊選衊糧夢鬱艱願蓋顧糧觸膚齋製淵獵 (糧夢願鹹餘繭淵顧夢廠, 34.9 ~ 90.1) 更多	-	2011-05-20